Plus Therapeutics Files 8-K
Ticker: PSTV · Form: 8-K · Filed: Mar 13, 2024 · CIK: 1095981
| Field | Detail |
|---|---|
| Company | Plus Therapeutics, Inc. (PSTV) |
| Form Type | 8-K |
| Filed Date | Mar 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, financials
TL;DR
PLUS files 8-K with Reg FD and financials.
AI Summary
On March 12, 2024, PLUS THERAPEUTICS, INC. (formerly CYTORI THERAPEUTICS, INC. and MACROPORE INC) filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. The company is incorporated in Delaware and headquartered in Austin, Texas.
Why It Matters
This 8-K filing provides important updates and disclosures from Plus Therapeutics, Inc., which could impact investor understanding of the company's current status and financial health.
Risk Assessment
Risk Level: low — This filing is a standard 8-K report for disclosures and exhibits, not indicating any immediate operational or financial distress.
Key Players & Entities
- PLUS THERAPEUTICS, INC. (company) — Registrant
- CYTORI THERAPEUTICS, INC. (company) — Former Company Name
- MACROPORE INC (company) — Former Company Name
- March 12, 2024 (date) — Date of Earliest Event Reported
- 4200 Marathon Blvd., Suite 200, Austin, Texas 78756 (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Plus Therapeutics, Inc.?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 12, 2024.
What are the former names of Plus Therapeutics, Inc. mentioned in the filing?
The former names of Plus Therapeutics, Inc. mentioned are CYTORI THERAPEUTICS, INC. and MACROPORE INC.
Where are Plus Therapeutics, Inc.'s principal executive offices located?
Plus Therapeutics, Inc.'s principal executive offices are located at 4200 Marathon Blvd., Suite 200, Austin, Texas 78756.
What is the company's fiscal year end?
The company's fiscal year end is December 31 (1231).
Filing Stats: 555 words · 2 min read · ~2 pages · Grade level 9.3 · Accepted 2024-03-13 08:01:00
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share PSTV The Nasdaq Capital M
Filing Documents
- d804804d8k.htm (8-K) — 24KB
- d804804dex991.htm (EX-99.1) — 40KB
- g804804ex99_1p10g1.jpg (GRAPHIC) — 219KB
- g804804ex99_1p11g1.jpg (GRAPHIC) — 287KB
- g804804ex99_1p12g1.jpg (GRAPHIC) — 243KB
- g804804ex99_1p13g1.jpg (GRAPHIC) — 175KB
- g804804ex99_1p14g1.jpg (GRAPHIC) — 266KB
- g804804ex99_1p15g1.jpg (GRAPHIC) — 198KB
- g804804ex99_1p16g1.jpg (GRAPHIC) — 188KB
- g804804ex99_1p17g1.jpg (GRAPHIC) — 251KB
- g804804ex99_1p18g1.jpg (GRAPHIC) — 251KB
- g804804ex99_1p19g1.jpg (GRAPHIC) — 243KB
- g804804ex99_1p1g1.jpg (GRAPHIC) — 236KB
- g804804ex99_1p20g1.jpg (GRAPHIC) — 178KB
- g804804ex99_1p21g1.jpg (GRAPHIC) — 284KB
- g804804ex99_1p22g1.jpg (GRAPHIC) — 217KB
- g804804ex99_1p23g1.jpg (GRAPHIC) — 186KB
- g804804ex99_1p24g1.jpg (GRAPHIC) — 233KB
- g804804ex99_1p25g1.jpg (GRAPHIC) — 271KB
- g804804ex99_1p26g1.jpg (GRAPHIC) — 235KB
- g804804ex99_1p27g1.jpg (GRAPHIC) — 247KB
- g804804ex99_1p28g1.jpg (GRAPHIC) — 240KB
- g804804ex99_1p29g1.jpg (GRAPHIC) — 243KB
- g804804ex99_1p2g1.jpg (GRAPHIC) — 440KB
- g804804ex99_1p30g1.jpg (GRAPHIC) — 145KB
- g804804ex99_1p31g1.jpg (GRAPHIC) — 293KB
- g804804ex99_1p32g1.jpg (GRAPHIC) — 212KB
- g804804ex99_1p33g1.jpg (GRAPHIC) — 182KB
- g804804ex99_1p34g1.jpg (GRAPHIC) — 262KB
- g804804ex99_1p35g1.jpg (GRAPHIC) — 218KB
- g804804ex99_1p36g1.jpg (GRAPHIC) — 255KB
- g804804ex99_1p37g1.jpg (GRAPHIC) — 206KB
- g804804ex99_1p38g1.jpg (GRAPHIC) — 252KB
- g804804ex99_1p39g1.jpg (GRAPHIC) — 258KB
- g804804ex99_1p3g1.jpg (GRAPHIC) — 277KB
- g804804ex99_1p4g1.jpg (GRAPHIC) — 274KB
- g804804ex99_1p5g1.jpg (GRAPHIC) — 202KB
- g804804ex99_1p6g1.jpg (GRAPHIC) — 229KB
- g804804ex99_1p7g1.jpg (GRAPHIC) — 182KB
- g804804ex99_1p8g1.jpg (GRAPHIC) — 220KB
- g804804ex99_1p9g1.jpg (GRAPHIC) — 161KB
- 0001193125-24-066407.txt ( ) — 12821KB
- pstv-20240312.xsd (EX-101.SCH) — 3KB
- pstv-20240312_lab.xml (EX-101.LAB) — 18KB
- pstv-20240312_pre.xml (EX-101.PRE) — 11KB
- d804804d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Investor Slides dated March 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PLUS THERAPEUTICS, INC. Date: March 13, 2024 By: /s/ Marc H. Hedrick, M.D. Name: Marc H. Hedrick, M.D. Title: President and Chief Executive Officer